文献速递白血病造血干细胞移植与细胞治疗

含CD28或4-1BB的第二代CD19 CAR-T治疗急性淋巴细胞白血病

Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
PubMed 文献 · Br J Haematol · 2018-04-10

研究用含CD28或4-1BB共刺激信号 second generation CD19 CAR-T治疗10例复发或难治性急性淋巴细胞白血病患者,前5例用CD28-CAR-T、后5例用4-1BB CAR-T,全部可评估疗效。CD28组3例完全缓解、1例髓外病变部分缓解;4-1BB组3例完全缓解。FLT3LG与缓解时间高度相关,10例均未观察到严重不良事件。

要点

  • CD28组5例中3例完全缓解、1例髓外病变部分缓解;4-1BB组5例中3例完全缓解。
  • FLT3LG与缓解时间高度相关,可能作为预后因素。
  • 10例接受治疗患者均未观察到严重不良事件。

核心结论

  • CD28 CAR-T与4-1BB CAR-T均对复发或难治性ALL产生缓解,但两者在反应模式(峰值反应时间、反应持续时间及反应程度)、不良事件、细胞因子分泌和免疫抑制因子水平方面存在差异。

研究设计与样本

  • 研究纳入10例复发或难治性急性淋巴细胞白血病患者,前5例接受CD28-CAR-T治疗,后5例接受4-1BB CAR-T治疗,全部10例均可进行疗效评估。

主要发现

  • CD28-CAR-T组5例中3例达到完全缓解,1例伴髓外病变者达到部分缓解。
  • 4-1BB CAR-T组5例中3例达到完全缓解。
  • FLT3LG与缓解时间高度相关,可能作为预后因素。
  • 10例接受治疗患者均未观察到严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T cells modified with anti-CD19 chimeric antigen receptor (CAR) containing either CD28 or 4-1BB (also termed TNFRSF9, CD137) costimulatory signalling have shown great potential in the treatment of acute lymphoblastic leukaemia (ALL). However, the difference between CD28 and 4-1BB costimulatory signalling in CAR-T treatment has not been well elucidated in clinical trials. In this study, we treated 10 relapsed or refractory ALL patients with the second generation CD19 CAR-T. The first 5 patients were treated with CD28-CAR and the other 5 patients were treated with 4-1BB CAR-T. All the 10 patients were response-evaluable. Three patients achieved complete remission and 1 patient with extramedullary disease achieved partial response after CD28-CAR-T treatment. In the 4-1BB CAR-T treatment group, 3 patients achieved complete remission. Furthermore, FLT-3 ligand (FLT3LG) was highly correlated with response time and may serve as a prognosis factor. No severe adverse events were observed in these 10 treated patients. Our study showed that both CD28 CAR-T and 4-1BB CAR-T both worked for response but they differed in response pattern (peak reaction time, reaction lasting time and reaction degree), adverse events, cytokine secretion and immune-suppressive factor level.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Li S, Zhang J, Wang M, et al. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br J Haematol. 2018. PMID: 29637550. doi:10.1111/bjh.15195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。